Top-line results from the Phase III ASCEND-4 study show that Novartis AG’s oral, selective inhibitor anaplastic lymphoma kinase (ALK) inhibitor Zykadia (ceritinib) has met its primary endpoint in improving progression-free survival compared with standard chemotherapy in the first-line treatment of patients with advanced anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC).
The data look set to propel the product into the frontline for advanced disease where it would go up against...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

